An investigation on behalf of investors in Fate Therapeutics, Inc. (NASDAQ: FATE) shares over potential wrongdoing at Fate Therapeutics, Inc. was announced and NASDAQ: FATE stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 08/10/2018 -- An investigation was announced for investors in shares of Fate Therapeutics, Inc. (NASDAQ: FATE) concerning potential breaches of fiduciary duties by certain officers and directors at Fate Therapeutics, Inc.
Investors who purchased shares of Fate Therapeutics, Inc. (NASDAQ: FATE) and currently hold any of those NASDAQ: FATE shares have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Fate Therapeutics officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.
San Diego, CA based Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Shares of Fate Therapeutics, Inc. grew from $1.48 per share in May 2016 to as high as $14.03 per share in February 2018.
On August 9, 2018, NASDAQ: FATE shares closed at $11.42 per share.
Those who purchased shares of Fate Therapeutics, Inc. (NASDAQ: FATE), have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels